Evaluation of Effectiveness and Safety of Antegrade and Retrograde Approach of Percutaneous Coronary Intervention for Chronic Total Occlusions

Launched by SEUNG-WHAN LEE, M.D., PH.D. · Sep 10, 2018

Keywords

ClinConnect Summary

This clinical trial is investigating two different methods for treating a condition called chronic total occlusion (CTO) of the coronary artery, where a blood vessel is completely blocked. The study aims to compare the effectiveness and safety of two approaches: the antegrade approach, where the procedure is done from the usual direction of blood flow, and the retrograde approach, where the procedure is done from the opposite direction. Researchers will look at how well each method works, the success rates, any complications that may occur, and the long-term health outcomes for patients after the procedure.

To participate in this trial, individuals must be at least 19 years old and have a blockage in one or more of their coronary arteries that is 2.5 mm or wider. They should also be experiencing symptoms like chest pain or have a diagnosed heart condition. Participants will receive care according to the trial's guidelines and will need to agree to follow-up appointments. It’s important to note that certain individuals, such as those who are pregnant, have severe health issues, or specific allergies, will not be eligible to join. If you or a loved one is considering this trial, it’s a great opportunity to contribute to research that may improve future heart treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged\>=19
• • Patients who have a CTO lesion in at least one or more epicardial coronary artery 2.5 mm in blood vessel diameter
• • Patients who have symptoms of angina or objectively proven myocardial ischemia (asymptomatic myocardial ischemia, stable or unstable angina, non - -ST-segment elevation myocardial infarction)
• • Patients who voluntarily agreed to the protocol and the clinical follow-up plan (or let their representative do this), and signed the informed consent form approved by the IRB of each study institute
• Exclusion Criteria:
• • Patients who are pregnant or lactating or have childbearing potential Patients in whom contrast medium and heparin are contraindicated or who are hypersensitive to them
• • Patients in whom aspirin, clopidogrel, ticagrelor and prasugrel, cilostazol are contraindicated
• • Patients scheduled to undergo a surgery, etc. that requires discontinuance of an antiplatelet drug within 12 months after participation in the study
• • Acute ST elevation myocardial infarction at the time of hospitalization
• • Terminally ill patients with their life expectancy \< one year
• • Patients who have serious diseases other than cardiac diseases that may affect limitation of residual life time or observation of the protocol (e.g. oxygen-independent chronic obstructive pulmonary disease, persisting hepatitis or serious hepatic insufficiency, severe renal disease, etc. Be left up to the discretion of the investigator.)